Tus kws kho mob
QP98-22 Commercial Pharmacy Benefit Exclusion for Cimerli™, Skysona®, Spevigo®, and Xenpozyme™
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 23, 2022
Tshawb Nrhiav
Nthuav pom cov txiaj ntsig tshwm sim 1131 - 1140 ntawm 4179
Tus kws kho mob
QP97-22 Update for New to Market Medical Drugs: etranacogene dezaparvovec
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 23, 2022
Tus kws kho mob
QP100-22 Service Area Expansion for Minnesota Health Care Programs (MHCP)
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 23, 2022
Tus kws kho mob
P25R1-20 Children’s Therapeutic Services and Supports (CTSS) Prior Authorization Requirement
Hnub Tim pib siv tau lub khoos kas: Lub Ob Hlis Ntuj Tim 01, 2023
Tus kws kho mob
QP112R1-20 Changes to Electronic Funds Transfer Processes
Hnub Tim pib siv tau lub khoos kas: Lub Ob Hlis Ntuj Tim 22, 2023
Tus kws kho mob
QP11-23 Commercial Pharmacy Benefit Exclusion for Cimzia®
Hnub Tim pib siv tau lub khoos kas: Lub Ob Hlis Ntuj Tim 22, 2023
Tus kws kho mob
QP12-23 Change in Prior Authorization Process for Experimental or Investigative Services
Hnub Tim pib siv tau lub khoos kas: Lub Ob Hlis Ntuj Tim 22, 2023
Tus kws kho mob
bc-mhcp-pharmprogpolicynotifctn-final-eff-3.1.23.pdf
Tus kws kho mob
QP6-23 Commercial Pharmacy Benefit Exclusion for Briumvi™, Hemgenix®, Rebyota™, and Sunlenca® Injection
Hnub Tim pib siv tau lub khoos kas: Lub Ob Hlis Ntuj Tim 08, 2023